AVITA Medical, Inc. (RCEL)
9.92
-0.14
(-1.39%)
USD |
NASDAQ |
Aug 24, 16:00
9.92
0.00 (0.00%)
After-Hours: 20:00
AVITA Medical Enterprise Value : 348.47M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 348.47M |
| August 20, 2026 | 349.40M |
| August 19, 2026 | 357.13M |
| August 18, 2026 | 341.98M |
| August 17, 2026 | 281.67M |
| August 14, 2026 | 280.12M |
| August 13, 2026 | 285.07M |
| August 12, 2026 | 288.47M |
| August 11, 2026 | 290.95M |
| August 10, 2026 | 272.39M |
| August 07, 2026 | 277.65M |
| August 06, 2026 | 184.25M |
| August 05, 2026 | 175.59M |
| August 04, 2026 | 180.54M |
| August 03, 2026 | 180.23M |
| July 31, 2026 | 173.42M |
| July 30, 2026 | 176.21M |
| July 29, 2026 | 174.66M |
| July 28, 2026 | 179.92M |
| July 27, 2026 | 184.25M |
| July 24, 2026 | 179.92M |
| July 23, 2026 | 179.92M |
| July 22, 2026 | 190.12M |
| July 21, 2026 | 194.76M |
| July 20, 2026 | 196.31M |
| Date | Value |
|---|---|
| July 17, 2026 | 195.07M |
| July 16, 2026 | 191.36M |
| July 15, 2026 | 183.63M |
| July 14, 2026 | 161.67M |
| July 13, 2026 | 159.51M |
| July 10, 2026 | 162.91M |
| July 09, 2026 | 173.73M |
| July 08, 2026 | 181.16M |
| July 07, 2026 | 191.98M |
| July 06, 2026 | 197.86M |
| July 02, 2026 | 193.84M |
| July 01, 2026 | 181.77M |
| June 30, 2026 | 165.07M |
| June 29, 2026 | 164.66M |
| June 26, 2026 | 156.04M |
| June 25, 2026 | 154.50M |
| June 24, 2026 | 155.43M |
| June 23, 2026 | 154.50M |
| June 22, 2026 | 157.89M |
| June 18, 2026 | 157.27M |
| June 17, 2026 | 155.12M |
| June 16, 2026 | 154.50M |
| June 15, 2026 | 154.81M |
| June 12, 2026 | 154.20M |
| June 11, 2026 | 156.04M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Halozyme Therapeutics, Inc. | 14.25B |
| Agenus, Inc. | 609.42M |
| Amgen, Inc. | 280.82B |
| Anika Therapeutics, Inc. | 278.32M |
| BioCryst Pharmaceuticals, Inc. | 2.921B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.663M |
| Revenue (Quarterly) | 21.70M |
| Total Expenses (Quarterly) | 29.36M |
| EPS Diluted (Quarterly) | -0.2492 |
| Gross Profit Margin (Quarterly) | 81.87% |
| Profit Margin (Quarterly) | -35.31% |
| Earnings Yield | -14.55% |
| Normalized Earnings Yield | -15.01 |